Ubs Asset Management Americas Inc Cure Vac N.V. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Cure Vac N.V. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 279,656 shares of CVAC stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
279,656
Previous 276,505
1.14%
Holding current value
$1.25 Million
Previous $942,000
17.83%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CVAC
# of Institutions
94Shares Held
10.7MCall Options Held
75.1KPut Options Held
86.7K-
Black Rock Inc. New York, NY2.25MShares$10.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.82MShares$8.12 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$7.01 Million10.6% of portfolio
-
Ubs Group Ag843KShares$3.77 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0308KShares$1.38 Million0.08% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $838M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...